Network Pharmacology-Based Investigation of the Therapeutic Mechanisms of Action of Danning Tablets in Nonalcoholic Fatty Liver Disease

Table 1

The information of the key bioactive compounds of DNt.

TCMSP ID	Name	Molecular formula	Structural formula	OB (%)	IEP	DL	Source	Degree value	Closeness centrality value
MOL000098	Quercetin	C15H10O7		46.43	0.05	0.28	PCRR, CF	41	0.53
MOL000006	Luteolin	C15H10O6		36.16	0.19	0.25	PCRR, CF	20	0.43
MOL000359	β-sitosterol	C29H50O		36.91	1.32	0.75	PCRR, IR, CRP, RRR, CR, CF	18	0.43
MOL004253	Curcumenolactone C	C15H20O4		39.7	0.16	0.19	CR	17	0.43
MOL001506	Supraene	C30H50		33.55	2.08	0.42	CF	17	0.41
MOL000422	Kaempferol	C15H10O6		41.88	0.26	0.24	CF	17	0.40
MOL000449	Stigmasterol	C29H48O		43.83	1.44	0.76	IR, CF	16	0.42

OB, oral bioavailability; IEP, intestinal epithelial permeability; DL, drug-likeness.